On May 30, 2024, Novo Nordisk, the manufacturer of the popular weight-loss drug Wegovy, initiated lawsuits against nine medical spas, clinics, and pharmacies, alleging that these providers distributed unauthorized versions of the drug. This legal action underscores a significant and emerging challenge for pharmacies dealing with complex issues related to compounding semaglutide and other GLP-1 receptor agonists.
This is not the first time GLP-1 manufacturers filed lawsuits against spas, clinics, and pharmacies. As we reported here, Eli Lilly filed lawsuits against medical spas, wellness centers, and compounding pharmacies in an effort to stop entities from selling compounded products containing tirzepatide, the GLP-1 receptor agonist in Eli Lilly’s medication Mounjaro, and using the trademarked name in its advertising of the compounded drug product. Similarly, in the Novo Nordisk’s lawsuits, the manufacturer claims – among other things – that these pharmacy providers are dispensing “copycat” versions of its FDA-approved products that do not contain the same drug components.
The distribution of unauthorized or compounded versions of patented drugs is a contentious issue. Pharmacies involved in these practices often find themselves navigating a complex web of federal and state regulations, intellectual property laws, and FDA guidelines. For example, compounded drugs cannot have any safety or efficacy claims because they are not FDA-approved. Even advertising FDA-approved indications is not allowed. A pharmacy cannot market compounded preparations as safe and effective for treating specific conditions unless the drug has been explicitly pre-approved by the FDA for those conditions. That’s not to say that compounding pharmacies cannot compound semaglutide or terzipatide, but these pharmacies must meet certain requirements of the Federal Food, Drug, and Cosmetic Act and US Pharmacopeia.
Novo Nordisk’s aggressive legal stance is a reminder of the heightened scrutiny and potential legal risks associated with compounding practices and the sale of non-FDA-approved versions of compound medications. Also, the lawsuits filed by Novo Nordisk are not isolated incidents but part of a broader trend where large pharmaceutical companies are increasingly vigilant in protecting their intellectual property rights and market share. This trend highlights the importance for pharmacies to stay informed about the legal risks associated with compounding and distributing patented drugs.
How Frier Levitt Can Help
Defending pharmacies against lawsuits from GLP-1 manufacturers like Novo Nordisk requires a sophisticated understanding of both the legal and regulatory landscapes. At Frier Levitt, we are committed to providing our clients with the expertise and support they need to navigate these challenges successfully. Our goal is to ensure that pharmacies can continue to serve their patients while complying with all relevant laws and regulations. Contact us today to speak with an attorney.
